On October 20, 2021 Doma announced the official start of its operation and plans to build its new drug development headquarters in Suzhou Industrial Park (Press release, Doma Biopharmaceutical, OCT 20, 2021, View Source [SID1234636132]). Doma was established in Suzhou BioBAY in September 2021. Led by Biocytogen and supported by three major central enterprises, China Life, PICC and State Development and Investment Corp., as well as CMB International and Suzhou Industrial Park, the project involves the joint construction of an innovative drug incubation center and the investment of the first phase is expected to exceed RMB 1 billion.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

By leveraging the innovative pipelines branched from the project integrum platform, Doma is committed to incubating new antibody drug companies in the park and establishing a new cradle of innovation for new drug development in China. the goal of the project integrum is to discover numerous potential first-in-class targets and novel antibody molecules over a period of 3-5 years. Incubatees in their early stages can leverage the large number of promising new targets and antibodies identified by the platform to reduce early-stage R&D spending and move their pipelines quickly into clinical stages, thereby greatly accelerating the R&D process

On October 20, 2021 Oxilio reported that it signed an exclusive global licensing agreement with TRx Biosciences Ltd, a privately held pharmaceutical development company, for its patent rights and know-how connected with the TRx platform technology (Press release, Oxilio, OCT 20, 2021, View Source [SID1234621599]). Oxilio will use this technology for the development and commercialisation of an optimised compound formulation in the field of cancer treatment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The TRx technology enables targeted oral drug delivery to specific organs, cells and tissues in cancer using a clinically and commercially proven approach.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 19, 2021 OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, reported two poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 36th Annual Meeting being held November 10-14, 2021, both virtually and in Washington, D.C (Press release, OncoMyx Therapeutics, OCT 19, 2021, View Source [SID1234594855]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Onsite posters will be presented in the Poster Hall at the Walter E. Washington Convention Center. The posters will be available for onsite viewing November 12-14 from 7am to 5pm EST. Even numbered posters will be presented Saturday, November 13. ePosters will be on display on the SITC (Free SITC Whitepaper) 2021 virtual meeting platform from 7am EST on Friday, November 12 until the virtual meeting platform is closed on January 9, 2022.

Titles of the presentations are as follows:

(742) Multi-armed myxoma virus induces potent anti-tumor responses in vitro and in vivo
(744) Multi-armed myxoma virus has therapeutic potential for treatment of multiple myeloma
Full abstracts will be available on November 9th on the SITC (Free SITC Whitepaper) 2021 Annual Meeting website. Posters for both presentations will be available on OncoMyx’s website on November 12th.

About Oncolytic Immunotherapy and Myxoma Virus

Oncolytic viruses (OV) selectively replicate in and lyse tumor cells and provide stimulation to the immune system, representing a promising therapeutic option in development to treat cancers that do not respond well tOncolytic viruses (OV) selectively replicate in and lyse tumor cells and provide stimulation to the immune system, representing a promising therapeutic option in development to treat cancers that do not respond well to treatment with immune checkpoint inhibitors. Myxoma virus (MYXV) is a member of the Pox family of double stranded DNA viruses. The natural host of MYXV is a subset of rabbits and hares, but MYXV is able to infect cancer cell lines of humans and other species. The genome of MYXV is relatively large and is amenable to engineering for expression of transgenic proteins, making it an excellent oncolytic virus for introduction of immunomodulatory proteins.

On October 20, 2021 Point32Health and Takeda Pharmaceuticals America, Inc. reported that they have signed an innovative risk-sharing agreement around Takeda’s ALUNBRIG (brigatinib), a potent and selective tyrosine kinase inhibitor (TKI) that is approved for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test (Press release, Takeda, OCT 20, 2021, View Source [SID1234594767]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The agreement will make ALUNBRIG broadly available to Point32Health’s more than two million members – with Takeda standing behind the medicine with a unique outcomes-based structure. The agreement is among the first risk-sharing contracts in oncology and the very first in ALK+NSCLC.

"Given the importance of facilitating cutting-edge oncology treatment and also the reality that not all patients show a positive response, reimbursement for oncology treatments is an area that is prime for innovative financing approaches," said Michael Sherman, MD, chief medical officer and executive vice president, Point32Health. "We’re excited to be able to demonstrate the value of ALUNBRIG as a treatment option for people with ALK+ NSCLC. Collaborating with Takeda to share risk makes this agreement a crucial milestone in bringing cost-effectiveness to cancer care."

"Takeda is committed to identifying and collaborating with payers on innovative and bold solutions that help ensure patients have access to our transformative therapeutics," said Dion Warren, vice president, head, U.S. Business Unit, Takeda Oncology. "Through this collaboration, Point32Health is able to allow broader access to ALUNBRIG because Takeda stands behind the value of its medicine and is willing to minimize the financial risk."